JP2022524914A5 - - Google Patents

Info

Publication number
JP2022524914A5
JP2022524914A5 JP2021542335A JP2021542335A JP2022524914A5 JP 2022524914 A5 JP2022524914 A5 JP 2022524914A5 JP 2021542335 A JP2021542335 A JP 2021542335A JP 2021542335 A JP2021542335 A JP 2021542335A JP 2022524914 A5 JP2022524914 A5 JP 2022524914A5
Authority
JP
Japan
Prior art keywords
carbon atoms
groups
unsubstituted
replaced
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021542335A
Other languages
English (en)
Japanese (ja)
Other versions
JP7600119B2 (ja
JP2022524914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/051347 external-priority patent/WO2020152132A1/en
Publication of JP2022524914A publication Critical patent/JP2022524914A/ja
Publication of JP2022524914A5 publication Critical patent/JP2022524914A5/ja
Application granted granted Critical
Publication of JP7600119B2 publication Critical patent/JP7600119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021542335A 2019-01-22 2020-01-21 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 Active JP7600119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19152961.9 2019-01-22
EP19152961 2019-01-22
PCT/EP2020/051347 WO2020152132A1 (en) 2019-01-22 2020-01-21 Thiazolopyridine derivatives as adenosine receptor antagonists

Publications (3)

Publication Number Publication Date
JP2022524914A JP2022524914A (ja) 2022-05-11
JP2022524914A5 true JP2022524914A5 (enExample) 2023-01-31
JP7600119B2 JP7600119B2 (ja) 2024-12-16

Family

ID=65199346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542335A Active JP7600119B2 (ja) 2019-01-22 2020-01-21 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体

Country Status (23)

Country Link
US (1) US12344623B2 (enExample)
EP (1) EP3914600B1 (enExample)
JP (1) JP7600119B2 (enExample)
KR (1) KR102891741B1 (enExample)
CN (1) CN113939520B (enExample)
AR (1) AR117844A1 (enExample)
AU (1) AU2020211697B2 (enExample)
BR (1) BR112021014406A2 (enExample)
CA (1) CA3127284A1 (enExample)
DK (1) DK3914600T3 (enExample)
ES (1) ES2992081T3 (enExample)
FI (1) FI3914600T3 (enExample)
HR (1) HRP20241385T1 (enExample)
HU (1) HUE068968T2 (enExample)
IL (1) IL285024A (enExample)
LT (1) LT3914600T (enExample)
MX (1) MX2021008510A (enExample)
PL (1) PL3914600T3 (enExample)
PT (1) PT3914600T (enExample)
RS (1) RS66038B1 (enExample)
SG (1) SG11202107858WA (enExample)
SI (1) SI3914600T1 (enExample)
WO (1) WO2020152132A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351640A1 (en) 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
CN119654328A (zh) 2022-08-02 2025-03-18 默克专利股份公司 (S)-7-氧杂-2-氮杂-螺[4.5]癸烷-2-甲酸[7-(3,6-二氢-2H-吡喃-4-基)-4-甲氧基-噻唑并[4,5-c]吡啶-2-基]-酰胺的新型结晶形式及其共晶形式
CN118206542B (zh) * 2023-03-22 2025-06-27 沈阳药科大学 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU2001281817B2 (en) * 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
US20080070932A1 (en) 2003-04-09 2008-03-20 Chi Vu Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
PT1636223E (pt) 2003-05-19 2008-05-06 F Hoffmann-La Roche Ag Derivados de benzotiazole como ligandos de receptores da adenosina
RU2006112847A (ru) * 2003-09-19 2007-11-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазолопиридина в качестве лигандов аденозинового рецептора
US7054288B2 (en) * 2004-02-13 2006-05-30 Interdigital Technology Corporation Method and apparatus for providing fast detection of a high speed shared control channel
DE102004008908A1 (de) * 2004-02-24 2005-09-08 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Ansteuerschaltung für Wandler
FR2867354A1 (fr) * 2004-03-09 2005-09-16 Joseph Vaillant Ferrure mecanique pour sabot, notamment pour cheval de sport
JP5202946B2 (ja) 2004-07-22 2013-06-05 エフ.ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
PL3634417T3 (pl) * 2017-05-17 2023-09-25 Arcus Biosciences, Inc. Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
PT3661941T (pt) * 2017-08-01 2023-03-16 Merck Patent Gmbh Derivados tiazolopiridina como antagonistas do recetor de adenosina

Similar Documents

Publication Publication Date Title
JP2022524914A5 (enExample)
JP2020531531A5 (enExample)
JP2020531526A5 (enExample)
RU2506256C2 (ru) Лиганды для визуализации иннервации сердца
RU2494095C2 (ru) Модифицированные миметики лизина
RU2009115653A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
JP2020528922A5 (enExample)
JP2006515858A5 (enExample)
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
JP2023504542A5 (enExample)
KR830007624A (ko) 헤테로 사이클릭 화합물의 제조방법
AR037972A1 (es) Pirrolopirimidinas
GB1046506A (en) Guanidine compounds and process for their manufacture
AR062299A1 (es) Derivados de bencimidazol
JP2005525392A5 (enExample)
RU2009125439A (ru) Комбинация ингибитора гда и антиметаболита
CA2518224A1 (en) Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
JP2025510945A5 (enExample)
JP2025160251A5 (enExample)
KR890016017A (ko) 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드
JP2023506005A5 (enExample)
RU97114846A (ru) Оптически активное производное тиазолидинона, способы его получения, композиция для профилактики и лечения стенокардии и язвенной болезни, применение тиа- или оксазолидинона
JP2021530465A5 (enExample)
JP2024546600A5 (enExample)
JP2005502722A5 (enExample)